The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet

Abstract

A recent large clinical study has shown that empagliflozin has a lower rate of cardiovascular and all-cause mortality when compared with placebo in patients with type 2 diabetes. We investigated the effect of empagliflozin (compared with glimepiride) on the progression of atherosclerosis, and its possible mechanisms of action. Forty-eight 5-week-old male… (More)
DOI: 10.1007/s00125-016-4158-2

Topics

9 Figures and Tables

Statistics

010020020172018
Citations per Year

84 Citations

Semantic Scholar estimates that this publication has 84 citations based on the available data.

See our FAQ for additional information.